of granulocytes. Transfusion 1980; 20:129.92 92. McCullough J, Clay ME, Loken MK, Hurd JJ. Effect of ABO incompatibility on fate in vivo of 111indium granulocytes. Transfusion 1988; 28:358.
93 93. Eyre HJ, Goldstein IM, Perry S, Graw RG Jr. Leukocyte transfusions: function of transfused granulocytes from donors with chronic myelocytic leukemia. Blood 1970; 36:432.
94 94. Applebaum FR, Trapani RJ, Graw RG. Consequences of prior alloimmunization during granulocyte transfusion. Transfusion 1977; 17:460.
95 95. McCullough J, Clay M, Hurd D, et al. Effect of leukocyte antibodies and HLA matching on the intravascular recovery, survival, and tissue localization of 111indium granulocytes. Blood 1986; 67:522.
96 96. Dutcher JP, Fox JJ, Riggs C, et al. Pulmonary retention of indium‐111‐ labeled granulocytes in alloimmunized patients. Blood 1982; 58:171 (abstract).
97 97. Pettengell R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82:3770–3777.
98 98. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r‐metHuG‐CSF): the first 10 years. Blood 1996; 88:1907–1929.
99 99. Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte‐macrophage colony‐stimulating factor on hematopoietic reconstitution after high‐dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318:869–876.
100 100. Bishop MR, Anderson JR, Jackson JD, et al. High‐dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte‐macrophage colony‐stimulating factor on the autograft. Blood 1994; 83:610–616.
101 101. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte‐macrophage colony‐stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324:1773–1778.
102 102. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81:3158–3163.
103 103. Korbling M, Huh YO, Durett A, et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor‐derived primitive hematopoietic progenitor cells (CD34+ Th‐1dim) and lymphoid subsets, and possible predictors of engraftment and graft‐versus‐host disease. Blood 1995; 86:2842–2848.
104 104. Bensinger WI, Clift RA, Anasetti C, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells 1996; 14:90–105.
105 105. Bensinger WI, Buckner CD, Shannon‐Dorcy K, et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88:4132–4138.
106 106. Nemunaitis J, Anasetti C, Storb R, et al. Phase II trial of recombinant human granulocyte‐macrophage colony‐stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 1992; 79:2572–2577.
107 107. Korbling M, Przepiorka D, Huh YO. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85:1659–1665.
108 108. Lickliter JD, McGlave PB, DeFor TE, et al. Matched‐pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation. Bone Marrow Transplant 2000; 26:723–728.
109 109. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA‐identical siblings with standard‐risk leukemia. Blood 2002; 100:761–767.
110 110. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97:3380–3389.
111 111. Weaver CH, Buckner CD, Longin K. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony‐stimulating factor. Blood 1993; 82:1981–1984.
112 112. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85:1413–1415.
113 113. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony‐stimulating factor). Blood 1995; 86:1666–1672.
114 114. Hillyer CE, Lackey DA, Hart KK, et al. CD34+ progenitors and colony‐forming units—granulocyte macrophages are recruited during large‐volume leukapheresis and concentrated by counterflow centrifugal elutriation. Transfusion 1993; 33:316–321.
115 115. Stroncek DF, Clay ME, Smith J, et al. Composition of peripheral blood progenitor cell components collected from healthy donors. Transfusion 1997; 37:411–417.
116 116. Korbling M, Przepiorka D, Gajewski J, et al. With first successful allogeneic transplantations of apheresis‐derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? Blood 1995; 86:1235–1239.
117 117. Bambi F, Faulkner LB, Azzari C, et al. Pediatric peripheral blood progenitor cell collection: Haemonetics MCS 3P versus COBE Spectra versus Fresenius AS104. Transfusion 1998; 38:70–74.
118 118. Rosenfeld CS, Cullis H, Tarosky T, Nemunaitis J. Peripheral blood stem cell collection using the small volume collection chamber in the Fenwal CS‐3000 Plus blood cell separator. Bone Marrow Transplant 1994; 13; 131–134.
119 119. Hitzler WE, Wolf S, Runkel S, Kunz‐Kostomanolakis M. Comparison of intermittent‐ and continuous‐flow cell separators for the collection of autologous peripheral blood progenitor cells in patients with hematologic malignancies. Transfusion 2001; 41:1562–1566.
120 120. Morton JA, Baker DP, Hutchins CJ, Durrant ST. The COBE Spectra cell separator is more effective than the Haemonetics MCS‐3P cell separator for peripheral blood progenitor cell harvest after mobilization with cyclophosphamide and filgrastim. Transfusion 1997; 37:631–633.
121 121. Stroncek DF, Clay ME, Smith J, et al. Changes in blood counts after the administration of granulocyte‐colony‐stimulating factor and the collection of peripheral blood stem cells from healthy donors. Transfusion 1996; 36:596–600.
122 122. Platzbecker U, Prange‐Krex G, Bornhauser M, et al. Spleen enlargement in healthy donors during G‐CSF mobilization of PBPCs. Transfusion 2001; 41:184–189.
123 123. Stroncek D, Shawker T, Follman D, et al. G‐CSF‐induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43:609–613.
124 124. Gansner JM, Rahmani M, Jonsson AH, et al. Plateletpheresis‐associated lymphopenia in frequent platelet donors. Blood 2019; 133:605–614.
125 125. Burger SR, Hubel AH, McCullough J. Development of an infusible‐grade solution for non‐cryopreserved hematopoietic cell storage. Cytotherapy 1999; 1:123–133.
126 126. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007; 21:101–117.
127 127. Runkel S, Hauabelt H, Hitzler W, Hellstern P. The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion 2005; 45:427–432.
128 128.
